# Multi-CAR-T Cells Targeting B Cell Lymphomas

> **NCT04429438** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 11 (estimated)

## Conditions studied

- B Cell Lymphoma (BCL)

## Interventions

- **BIOLOGICAL:** 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2

## Key facts

- **NCT ID:** NCT04429438
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 11 (ESTIMATED)
- **Last updated:** 2020-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04429438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04429438, "Multi-CAR-T Cells Targeting B Cell Lymphomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04429438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*